India, July 11 -- Shares of MiNK Therapeutics Inc. (INKT) are up over 175% % at $21 in premarket trading today, following a promising update on its investigational cell therapy, AgenT-797.
AgenT-797 is an allogeneic off-the-shelf invariant Natural Killer T (iNKT) cell therapy, currently being studied in a phase I study for relapsed/refractory solid tumors and a phase II trial in second-line gastric cancer.
A new publication in the journal Oncogene highlights a landmark case from the phase I study in which a patient with metastatic, treatment-refractory testicular cancer achieved a complete and durable remission, following treatment with AgenT-797. The patient remains disease-free over two years after treatment.
This case reinforces the d...